JWA
NVCR icon

JFS Wealth Advisors’s NovoCure NVCR Stock Holding History

JFS Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$73 – 1982
2022
Q4 		$73 Buy
+1
New +$75 ﹤0.01% 1902
2022
Q2 		– Sell
-29
Closed -$2K – 1878
2022
Q1 		$2K Sell
29
-74
-72% -$5.45K ﹤0.01% 1463
2021
Q4 		$8K Buy
103
+3
+3% +$301 ﹤0.01% 725
2021
Q3 		$12K Buy
+100
New +$15.1K ﹤0.01% 619

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

JFS Wealth Advisors's NVCR Position: Q1 2023 in Review

JFS Wealth Advisors sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 1 share — an estimated $73 sold.

JFS Wealth Advisors first reported a position in NVCR in Q3 2021 and held it in 4 quarters. The position peaked at $12K in Q3 2021. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

  • JFS Wealth Advisors reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
  • JFS Wealth Advisors sold 1 NovoCure share in Q1 2023, an estimated $73.
  • JFS Wealth Advisors first reported a position in NovoCure in Q3 2021 and held it in 4 quarters.
  • JFS Wealth Advisors's NovoCure position peaked at $12K in Q3 2021.
  • 295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on JFS Wealth Advisors's 13F filing for Q1 2023, filed 19 Apr 2023.